OVID News and Press, Ovid Therapeutics Inc. From 04/20/21

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D.,...

Ovid Therapeutics (OVID) has slipped 3.2% postmarket after a downgrade to Neutral at Cantor Fitzgerald, pointing to decisions to discard development of approaches to Angelman syndrome and Fragile X syndrome. The company is refocusing on development of its early-stage pipeline, including OV882...

Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID’s Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly Operating Expenses Guidance of Between $8 Million and $10 Millio...

Will These Penny Stocks Grow As The Biotech Sector Pushes Up? With penny stocks, high volatility can often be used as an asset. While buying penny stocks is not for everyone, the potential with stocks under $5 can be high. On the other hand, some investors will shy away from penny...

Gainers: [[CAN]] +8.6%. [[NLOK]] +8.3%. [[QK]] +8.1%. [[QTRX]] +5.2%. [[DBTX]] +4.5%.Losers: [[KELYB]] -7.8%. [[PFIN]] -4.7%. [[OVID]] -3.7%. [[HPK]] -3.2%. [[RMNI]] -2.3%. For further details see: QTRX, QK, PFIN and OVID among after-hours movers

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the closing of the Royalty, License an...

Ovid Therapeutics (OVID): Q4 GAAP EPS of -$0.34 misses by $0.04.Revenue of $5.7M beats by $1.54M.Press Release For further details see: Ovid Therapeutics EPS misses by $0.04, beats on revenue

Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing Two ...

RBC Capital Markets analyst Brian Abrahams has downgraded shares of Ovid Therapeutics Inc. (OVID) to sector perform from outperform but is maintaining his price target of $5.Shares of Ovid are up 34% to $3.97 in afternoon trading after the company's announcement this morning that Ta...

Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceutica...